摘要
目的:分析BD(硼替佐米+地塞米松)、BAD(硼替佐米+地塞米松+阿霉素)化疗方案治疗多发性骨髓瘤(MM)的疗效。方法:MM患者90例,采用BD、BAD方案化疗各45例,均治疗4个疗程后评估疗效,比较两组化疗前后血清胱抑素C(Cys-C)、尿素(Urea)、肌酐(Scr)、β2-微球蛋白(β2-MG)水平及骨髓瘤细胞比例,比较两组不良反应发生率和复发率。结果:BAD组总有效率93. 3%,高于BD组的73. 3%(P <0. 05)。BAD组、BD组不良反应发生率分别为28. 9%、22. 2%,复发率分别为8. 9%、13. 3%,差异均无统计学意义(P> 0. 05)。化疗后两组血清Cys-C、Urea、Scr、β2-MG及骨髓瘤细胞比例均较治疗前下降,且BAD组下降幅度大于BD组(P <0. 05)。结论:BD、BAD化疗方案对MM均有一定疗效,BAD方案优于BD方案。
Aim:To analyze the efficacy of BD(bortezomib plus dexamethasone)and BAD(bortezomib plus dexamethasone plus adriamycin)chemotherapy regimens for multiple myeloma(MM).Methods:A total of 90 patients with MM were randomly allocated into two groups,45 cases received BD chemotherapy regimen(BD group),and the other 45 cases received BAD chemotherapy for 4 courses of treatment.The levels of serum Cystatin C(Cys-C),Urea,creatinine(Scr),β2-microglobulin(β2-MG),and the proportion of myeloma cells were detected before and after chemotherapy.The incidence of adverse reactions and recurrence rate were recorded.Results:The total effective rate of BAD group was 93.3%,higher than that(73.3%)of BD group(P<0.05).The incidence of adverse reactions of BAD and BD groups was 28.9%,22.2%,recurrence rate was 8.9%,13.3%,respectively,and there was no significant differences between the two groups(P>0.05).The levels of serum Cys-C,Urea,Scr,β2-MG and the proportion of myeloma cells after chemotherapy in both groups were decreased compared with those before chemotherapy,especially in BAD group(P<0.05).Conclusion:Both BD and BAD chemotherapy regimens are effective for MM treatment,and BAD regimen may be superior.
作者
郑琳
陈果
李黎博
ZHENG Lin;CHEN Guo;LI Libo(Department of Hematology,the Third People′s Hospital of Chengdu,Chengdu 610031)
出处
《郑州大学学报（医学版）》
CAS
北大核心
2019年第3期435-438,共4页
Journal of Zhengzhou University(Medical Sciences)
基金
四川省医学会基金项目(Q150116)
关键词
BD方案
BAD方案
多发性骨髓瘤
肾功能
BD chemotherapy regimen
BAD chemotherapy regimen
multiple myeloma
renal function
